# US 2025/0367471 A1 · Perfusion modulated tumor dose sculpting with single dose radiotherapy

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2025/0367471 A1
- Document ID: US20250367471A1
- Status: Published application
- Kind: A1
- Application number: 19/012,179
- Filed: 2025-01-07
- Published: 2025-12-04
- Earliest claimed: 2019-07-31
- Assignees: Memorial Sloan Kettering Cancer Center; Fundação D. Anna de Sommer Champalimaud e Dr. Carlos Montez Champalimaud
- Applicants: Memorial Sloan Kettering Cancer Center; FundaçãO D. Anna De Sommer Champalimaud E Dr. Carlos Montez Champalimaud
- Inventors: Richard KOLESNICK; Zvi FUKS; Carlo GRECO
- Web page: https://patentgrep.com/patent/US20250367471A1

## CPC

- A61N 5/1031: {using a specific method of dose optimization}
- A61K 41/0038: {Radiosensitizing, i.e. administration of pharmaceutical agents that enhance the effect of radiotherapy (radiotherapy per se A61N5/10)}
- A61N 2005/1087: {Ions; Protons}
- A61N 2005/1098: {Enhancing the effect of the particle by an injected agent or implanted device}
- A61N: ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY (measurement of bioelectric currents A61B; surgical instruments, devices or methods for transferring non-mechanical forms of energy to or from the body A61B18/00; anaesthetic apparatus in general A61M; incandescent lamps H01K; infrared radiators for heating H05B)
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)

## Abstract

The present disclosure provides methods and systems for treating tumors with radiotherapy, wherein a first dose of radiation is administered to a first sub-volume of the tumor and a second dose of radiation is administered to a second sub-volume of the tumor.

## Claims

### Claim 1

A method of treating a tumor in a subject in need thereof, said tumor comprising:
a total planning target volume (PTVTOTAL) comprising the tumor's total volume, wherein the PTVTOTAL comprises a first planning target sub-volume (PTVHD) and a second planning target sub-volume (PTVPMDS);
wherein the method comprises delivering a radiation dose to each of the PTVPMDS and PTVHD, wherein the dose of radiation delivered to the PTVPMDS is lower than the dose of radiation delivered to the PTVHD, and
wherein the dose of radiation delivered to the PTVPMDS is insufficient to treat the tumor when delivered to the entirety of the PTVTOTAL.

### Claim 2 (depends on 1)

The method of claim 1, wherein the PTVHD comprises at least 60% of the PTVTOTAL.

### Claim 3 (depends on 1)

The method of claim 1, wherein the PTVHD comprises at least 60% of the tumor's total volume.

### Claim 4 (depends on 1, 2, 3)

The method of any one of claims 1-3, wherein the PTVPMDS comprises 40% or less of the PTVTOTAL.

### Claim 5 (depends on 1, 2, 3, 4)

The method of any one of claims 1-4, wherein the PTVPMDS comprises at least 5% of the PTVTOTAL.

### Claim 6 (depends on 1, 2, 3, 4)

The method of any one of claims 1-4, wherein the PTVPMDS Comprises at least 5% of the tumor's total volume.

### Claim 7 (depends on 1, 2, 3, 4, 5, 6)

The method of any one of claims 1-6, wherein the tumor is adjacent to a dose limiting organ at risk (OAR).

### Claim 8 (depends on 7)

The method of claim 7, wherein the OAR is a serial OAR.

### Claim 9 (depends on 1, 2, 3, 4, 5, 6, 7, 8)

The method of any one of claims 1-8, wherein the dose of radiation delivered to the PTVHD is at least 18 Gy, at least 19 Gy, at least 20 Gy, at least 21 Gy, at least 22 Gy, at least 23 Gy, at least 24 Gy, at least 25 Gy, or at least 26 Gy.

### Claim 10 (depends on 9)

The method of claim 9, wherein the dose of radiation delivered to the PTVHD is between about 22 Gy and about 25 Gy.

### Claim 11 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10)

The method of any one of claims 1-10, wherein the dose of radiation delivered to the PTVPMDS is less than about 23 Gy.

### Claim 12 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10)

The method of any one of claims 1-10, wherein the dose of radiation delivered to the PTVPMDS is between about 12 Gy and 23 Gy.

### Claim 13 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10)

The method of any one of claims 1-10, wherein the dose of radiation delivered to the PTVPMDS is less than about 18 Gy.

### Claim 14 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10)

The method of any one of claims 1-10, wherein the dose of radiation delivered to the PTVPMDS is between about 12 Gy and 18 Gy.

### Claim 15 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10)

The method of any one of claims 1-10, wherein the dose of radiation delivered to the PTVPMDS is less than about 12 Gy.

### Claim 16 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15)

The method of any one of claims 1-15, wherein the dose of radiation delivered to the PTVPMDS is at least 10% lower than the dose of radiation delivered to the PTVHD.

### Claim 17 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15)

The method of any one of claims 1-15, wherein the dose of radiation delivered to the PTVPMDS is between about 10% and about 50% lower than the dose of radiation delivered to the PTVHD.

### Claim 18 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15)

The method of any one of claims 1-15, wherein the dose of radiation delivered to the PTVPMDS is at least 50% lower than the dose of radiation delivered to the PTVHD.

### Claim 19 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18)

The method of any one of claims 1-18, wherein the dose of radiation delivered to 99% of the PTVPMDS (PTVPMDS-D99) is at least 20% lower than the dose of radiation delivered to 99% of the PTVHD (PTVHD-D99).

### Claim 20 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18)

The method of any one of claims 1-18, wherein the dose of radiation delivered to 95% of the PTVPMDS (PTVPMDS-D95) is at least 20% lower than the dose of radiation delivered to 95% of the PTVHD (PTVHD-D95).

### Claim 21 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20)

The method of any one of claims 1-20, wherein the method reduces incidence of local relapse compared to fractionated radiotherapy methods.

### Claim 22 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21)

The method of any one of claims 1-21, wherein the dose of radiation delivered to the PTVHD and the dose of radiation delivered to the PTVPMDS are delivered in the same treatment session.

### Claim 23 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22)

The method of any one of claims 1-22, wherein the dose of radiation delivered to the PTVHD and the dose of radiation delivered to the PTVPMDS are delivered simultaneously in the same treatment session.

### Claim 24

A system comprising:
a) a radiation source; and
b) an electronic device, the electronic device including at least a memory and a processor operatively coupled to the memory and configured to execute instructions stored on the memory, the processor configured to:
i) define a total planning target volume (PTVTOTAL) comprising the tumor's total volume, wherein said PTVTOTAL comprises a first planning target sub-volume (PTVHD) and a second planning target sub-volume (PTVPMDS);
ii) define a radiotherapy treatment plan for said PTVTOTAL; and
iii) send, to the radiation source, a signal indicative of an instruction to deliver radiation doses to the PTVTOTAL, wherein the dose of radiation delivered to the PTVPMDS is less the dose of radiation delivered to the PTVHD;
wherein the dose of radiation delivered to the PTVPMDS is insufficient to treat the tumor when delivered to the entirety of the PTVTOTAL.

### Claim 25 (depends on 24)

The system of claim 24, wherein the radiation source is selected from the group consisting of an x-ray emitter, an electron beam emitter, a proton beam emitter, and a linear accelerator.

### Claim 26 (depends on 24)

The system of claim 24, wherein the radiation source comprises a radioactive element selected from the group consisting of radioactive cesium, iridium, iodine, cobalt, and combinations thereof.

### Claim 27 (depends on 24, 25, 26)

The system of any one of claim 24-26, wherein the PTVHD comprises at least 60% of the PTVTOTAL.

### Claim 28 (depends on 24, 25, 26)

The system of any one of claim 24-26, wherein the PTVHD Comprises at least 60% of the tumor's total volume.

### Claim 29 (depends on 24, 25, 26, 27)

The system of any one of claim 24-27, wherein the PTVPMDS comprises 40% or less of the PTVTOTAL.

### Claim 30 (depends on 24, 25, 26, 27, 28, 29)

The system of any one of claim 24-29, wherein the PTVPMDS comprises at least 5% of the PTVTOTAL.

### Claim 31 (depends on 24, 25, 26, 27, 28, 29)

The system of any one of claim 24-29, wherein the PTVPMDS comprises at least 5% of the tumor's total volume.

### Claim 32 (depends on 24, 25, 26, 27, 28, 29, 30, 31)

The system of any one of claims 24-31, wherein the tumor is adjacent to a dose limiting organ at risk (OAR).

### Claim 33 (depends on 32)

The system of claim 32, wherein the OAR is a serial OAR.

### Claim 34 (depends on 24, 25, 26, 27, 28, 29, 30, 31, 32, 33)

The system of any one of claims 24-33, wherein the dose of radiation delivered to the PTVHD is at least 18 Gy, at least 19 Gy, at least 20 Gy, at least 21 Gy, at least 22 Gy, at least 23 Gy, at least 24 Gy, at least 25 Gy, or at least 26 Gy.

### Claim 35 (depends on 34)

The system of claim 34, wherein the dose of radiation delivered to the PTVHD is between about 22 Gy and about 25 Gy.

### Claim 36 (depends on 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35)

The system of any one of claim 24-35, wherein the dose of radiation delivered to the PTVPMDS is less than about 23 Gy.

### Claim 37 (depends on 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35)

The system of any one of claim 24-35, wherein the dose of radiation delivered to the PTVPMDS is between about 12 Gy and 23 Gy.

### Claim 38 (depends on 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35)

The system of any one of claims 24-35, wherein the dose of radiation delivered to the PTVPMDS is less than about 18 Gy.

### Claim 39 (depends on 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35)

The system of any one of claims 24-35, wherein the dose of radiation delivered to the PTVPMDS is between about 12 Gy and 18 Gy.

### Claim 40 (depends on 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35)

The system of any one of claims 24-35, wherein the dose of radiation delivered to the PTVPMDS is less than about 12 Gy.

### Claim 41 (depends on 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40)

The system of any one of claim 24-40, wherein the dose of radiation delivered to the PTVPMDS is at least about 10% lower than the dose of radiation delivered to the PTVHD.

### Claim 42 (depends on 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40)

The system of any one of claim 24-40, wherein the dose of radiation delivered to the PTVPMDS is between about 10% and 50% lower than the dose of radiation delivered to the PTVHD.

### Claim 43 (depends on 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40)

The system of any one of claim 24-40, wherein the dose of radiation delivered to the PTVPMDS is at least 50% lower than the dose of radiation delivered to the PTVHD.

### Claim 44 (depends on 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43)

The system of any one of claim 24-43, wherein the dose of radiation delivered to 99% of the PTVPMDS (PTVPMDS-D99) is at least 20% lower than the dose of radiation delivered to 99% of the PTVHD (PTVHD-D99).

### Claim 45 (depends on 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43)

The system of any one of claim 24-43, wherein the dose of radiation delivered to 95% of the PTVPMDS (PTVPMDS-D95) is at least 20% lower than the dose of radiation delivered to 95% of the PTVHD (PTVHD-D95).

### Claim 46 (depends on 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45)

The system of any one of claims 24-45, wherein the dose of radiation delivered to the PTVHD and the dose of radiation delivered to the PTVPMDS are delivered in the same treatment session.

### Claim 47 (depends on 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46)

The system of any one of claims 24-46, wherein the dose of radiation delivered to the PTVHD and the dose of radiation delivered to the PTVPMDS are delivered simultaneously in the same treatment session.

### Claim 48

The system of any of the preceding claims, wherein the electronic device is in communication with the radiation source via a network.

### Claim 49 (depends on 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47)

The system of any one of claims 24-47, wherein the electronic device and the radiation source are included in a single machine.

### Claim 50

The system of any of the preceding claims, further comprising:
an imaging device configured to capture one or more images of the tumor,
wherein the processor is configured to define the PTVTOTAL based at least in part on the one or more images of the tumor captured by the imaging device.

### Claim 51 (depends on 50)

The system of claim 50, wherein the imaging device and the radiation source are included in the same machine.

### Claim 52 (depends on 50, 51)

The system of claim 50 or 51, wherein the imaging device and the electronic device are included in the same machine.

### Claim 53 (depends on 50, 51)

The system of claim 50 or 51, wherein the imaging device is in communication with the electronic device via a network.

### Claim 54

A method of treating a tumor in a subject in need thereof comprising:
defining, at a processor, a total planning target volume (PTVTOTAL) of the tumor;
dividing, at the processor, the PTVTOTAL of the tumor into at least a first planning target sub-volume (PTVHD) and a second planning target sub-volume (PTVPMDS);
sending, from the processor and to a radiation source, a signal associated with a perfusion modulated dose sculpting (PMDS) radiotherapy plan; and
delivering, from the radiation source, a dose of radiation to each of the PTVHD and the PTVPMDS based on the PMDS radiotherapy plan,
wherein the dose of radiation covering 95% of the PTVPMDS (PTVPMDS-D95) is lower than the dose of radiation covering 95% of the PTVHD (PTVHD-D95) and wherein the PTVPMDS-D95 is lower than the dose of radiation covering 95% of the total PTV (PTVTOTAL-D95) required to treat the tumor.

### Claim 55 (depends on 54)

The method of claim 54, wherein the PTVHD comprises at least 60% of the total PTVTOTAL.

### Claim 56 (depends on 54)

The method of claim 54, wherein the PTVHD comprises at least 60% of the tumor.

### Claim 57 (depends on 54, 55, 56)

The method of any one of claim 54-56, wherein the PTVPMDS comprises 40% or less of the PTVTOTAL.

### Claim 58 (depends on 54, 55, 56, 57)

The method of any one of claims 54-57, wherein the PTVPMDS comprises at least 5% of the PTVTOTAL.

### Claim 59 (depends on 54, 55, 56, 57)

The method of any one of claims 54-57, wherein the PTVPMDS comprises at least 5% of the tumor.

### Claim 60 (depends on 54, 55, 56, 57, 58, 59)

The method of any one of claims 54-59, wherein the tumor is adjacent to a dose limiting organ at risk (OAR).

### Claim 61 (depends on 60)

The method of claim 60, wherein the OAR is a serial OAR.

### Claim 62 (depends on 54, 55, 56, 57, 58, 59, 60, 61)

The method of any one of claims 54-61, wherein the PTVHD-D95 is at least 18 Gy, at least 19 Gy, at least 20 Gy, at least 21 Gy, at least 22 Gy, at least 23 Gy, at least 24 Gy, at least 25 Gy, or at least 26 Gy.

### Claim 63 (depends on 62)

The method of claim 62, wherein the PTVHD-D95 is between about 22 Gy and about 25 Gy.

### Claim 64 (depends on 54, 55, 56, 57, 58, 59, 60, 61, 62, 63)

The method of any one of claims 54-63, wherein the PTVPMDS-D95 is less than about 23 Gy.

### Claim 65 (depends on 54, 55, 56, 57, 58, 59, 60, 61, 62, 63)

The method of any one of claims 54-63, wherein the PTVPMDS-D95 is between about 12 Gy and 23 Gy.

### Claim 66 (depends on 54, 55, 56, 57, 58, 59, 60, 61, 62, 63)

The method of any one of claims 54-63, wherein the PTVPMDS-D95 is less than about 18 Gy.

### Claim 67 (depends on 54, 55, 56, 57, 58, 59, 60, 61, 62, 63)

The method of any one of claims 54-63, wherein the PTVPMDS-D95 is between about 12 Gy and 18 Gy.

### Claim 68 (depends on 54, 55, 56, 57, 58, 59, 60, 61, 62, 63)

The method of any one of claims 54-63, wherein the PTVPMDS-D95 is less than about 12 Gy.

### Claim 69 (depends on 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68)

The method of any one of claims 54-68, wherein the PTVPMDS-D95 is at least 10% lower than the PTVHD-D95.

### Claim 70 (depends on 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68)

The method of any one of claims 54-68, wherein the PTVPMDS-D95 is between about 10% and about 50% lower than the PTVHD-D95.

### Claim 71 (depends on 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68)

The method of any one of claims 54-68, wherein the PTVPMDS-D95 is at least 50% lower than the PTVHD-D95.

### Claim 72 (depends on 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, 70, 71)

The method of any one of claims 54-71, wherein the PTVPMDS-D95 is at least 10% lower than the PTVTOTAL-D95 required to treat the tumor.

### Claim 73 (depends on 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, 70, 71)

The method of any one of claims 54-71, wherein the PTVPMDS-D95 is between about 10% and about 50% lower than the PTVTOTAL-D95 required to treat the tumor.

### Claim 74 (depends on 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, 70, 71)

The method of any one of claims 54-71, wherein the PTVPMDS-D95 is at least 50% lower than the PTVTOTAL-D95 required to treat the tumor.

### Claim 75 (depends on 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, 70, 71, 72, 73, 74)

The method of any one of claims 54-74, wherein the method reduces incidence of local relapse compared to fractionated radiotherapy methods.

### Claim 76 (depends on 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, 70, 71, 72, 73, 74, 75)

The method of any one of claims 54-75 wherein the doses of radiation are delivered to the PTVHD and the PTVPMDS in the same treatment session.

### Claim 77 (depends on 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, 70, 71, 72, 73, 74, 75, 76)

The method of any one of claims 54-76, wherein the doses of radiation are delivered to the PTVHD and the PTVPMDS simultaneously in the same treatment session.

### Claim 78

The method of any of the preceding claims, wherein sending the signal from the processor to the radiation source includes sending the signal via a network.

### Claim 79 (depends on 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, 70, 71, 72, 73, 74, 75, 76, 77)

The method of any one of claims 54-77, wherein the processor is included in an electronic device having at least the processor and a memory; and
wherein the electronic device and the radiation source are included in a single machine.

### Claim 80

The method of any of the preceding claims, further comprising:
capturing one or more images of the tumor via an imaging device; and
sending, from the imaging device and to the processor, data associated with the one or more images;
wherein the processor is configured to define the PTVTOTAL based at least in part on the data associated with the one or more images of the tumor.

### Claim 81 (depends on 80)

The method of claim 80, wherein the imaging device and the radiation source are included in the same machine.

### Claim 82 (depends on 80, 81)

The method of claim 80 or 81, wherein the processor is included in an electronic device having at least the processor and a memory; and
wherein the electronic device and the imaging device are included in a single machine.

### Claim 83 (depends on 80, 81)

The method of claim 80 or 81, wherein the imaging device is in communication with the electronic device via a network.

### Claim 84

A method of defining a perfusion modulated dose sculpting (PMDS) radiotherapy plan for treating a tumor in a subject in need thereof, the method comprising:
defining, at a processor, a total planning target volume (PTVTOTAL) of the tumor;
dividing, at the processor, the PTVTOTAL of the tumor into at least a first planning target sub-volume (PTVHD) and a second planning target sub-volume (PTVPMDS);
defining a dose of radiation for each of the PTVHD and the PTVPMDS; and
defining the PMDS radiotherapy plan for treating the tumor wherein the dose of radiation covering 95% of the PTVPMDS (PTVPMDS-D95) is lower than the dose of radiation covering 95% of the PTVHD (PTVHD-D95) and wherein the PTVPMDS-D95 is lower than the dose of radiation covering 95% of the total PTV (PTVTOTAL-D95) required to treat the tumor.

### Claim 85 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23)

The method of any one of claims 1-23, wherein the method further comprises administering a radio-sensitizing agent to the subject prior to delivering the radiation to the subject.

### Claim 86 (depends on 85)

The method of claim 85, wherein the radio-sensitizing agent is an ASMase/Ceramide activating agent selected from a vector comprising a polynucleotide encoding the ASMase protein, an anti-angiogenic agent (AAA), a composition comprising ceramide, a recombinant ASMase protein, a ceramidase antagonist, and a sphingosine kinase antagonist.

### Claim 87 (depends on 85)

The method of claim 85, wherein the radio-sensitizing agent is an ASMase/Ceramide activating agent selected from a protein kinase C (PKC) activator, TNF-alpha, an agent that downregulates or inhibits the expression and/or activity of caveolin-1 (CAV1), CD95 (Fas/APO-1), lipopolysaccharide (LPS), Palmitic acid (PA), lysobisphophatidic acid (LBPA), and phosphatidylinositol (PI).

### Claim 88 (depends on 85)

The method of claim 85, wherein the radio-sensitizing agent is selected from the group consisting of fluoropyrimidine, gemcitabine, a platinum analog such as cisplatin, NBTXR3, Nimoral, trans sodium crocetinate (TSC), NVX-108, misonidazole, metronidazole, tirapazamine, vandate, nitroimidazole alkylsulfonamides, ATR inhibitor AZD6738, taxane containing at least 2 electron-affinic radiosensitizing functional groups, 2-carboxyaldehyde pyridine thiosemicarbazone compound or prodrug thereof, substituted diamines containing 2-4 electron-affinic radiosensitizing functional groups, lanthanide-based nanoparticles, platinum complexes with one radiosensitizing ligand, indazolpyrrolotriazines, anthraquinones, and monomethyl auristatin e (mmae) and derivatives thereof.

### Claim 89 (depends on 85)

The method of claim 85, wherein the sensitizing agent is selected from the group consisting of a fluorocarbon, a halogenated nucleoside or its analog, a poly-(ADP-ribose)-polymerase (PARP) inhibitor, a histone H3 demethylase inhibitor, and a histone deacetylase (HDAC) inhibitor.

### Claim 90 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 85, 86, 87, 88, 89)

The method of any one of claims 1-23 and 85-89, wherein the radiation is delivered from a radiation source selected from the group consisting of an x-ray emitter, an electron beam emitter, a proton beam emitter, and a linear accelerator.

### Claim 91 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 85, 86, 87, 88, 89)

The method of any one of claims 1-23 and 85-89, wherein the radiation is delivered from a radiation source comprising a radioactive element selected from the group consisting of radioactive cesium, iridium, iodine, cobalt, and combinations thereof.
